360 HealthTech Pte. Ltd.
CPS 9Healthcare technology company providing digital health solutions and services.
360 HealthTech Pte. Ltd. is a Singapore-incorporated micro-SME described as providing healthcare technology consulting to healthcare organizations, with no verified robotics products, deployments, customers, revenue, leadership team, or intellectual property. Contradictory third-party data on funding status, absence of any public financial disclosures, and a competitor set aligned with RCM/BPO services rather than robotics or autonomous systems make this company uninvestable as a robotics/AS play and raise transparency concerns even as a general healthtech entity.
- No identified proprietary technology, patents, or intellectual property - No verified customer relationships or switching-cost-generating deployments - No disclosed partnerships with AMR OEMs or hospital systems that would create integration lock-in - Undifferentiated healthcare IT consulting positioning in a market with nearly 6,000 active competitors per Tracxn
No leadership team, founders, board members, clinical advisors, or technical leads are disclosed in any publicly available source reviewed. This complete absence of governance transparency is atypical even for early-stage companies and represents a material risk for any investor or partner conducting diligence.
— Domiciled in Singapore, which has a constructive healthcare innovation ecosystem with supportive government policies and leading hospital groups actively adopting AI and automation (HealthTech X Asia conference takeaways; LinkedIn Pulse market summary).
— Singapore's hospital AMR and healthcare robotics market is projected to grow at double-digit CAGRs (14.5–20%), creating a favorable macro backdrop if the company were to pivot toward systems integration or automation services (LinkedIn Pulse market summary, 2026; Cognitive Market Research, 2026).
— As a small, early-stage firm (founded 2020), 360 HealthTech has theoretical agility to reposition toward higher-value niches such as hospital AMR systems integration or narrow software layers (orchestration, analytics) if it secures the right partnerships and talent.
— Low regulatory friction for IT consulting relative to medical device/robotics certification provides a lower-barrier entry point from which to build hospital relationships before pursuing more complex automation engagements.
— No verified robotics products, AMR platforms, patents, safety certifications, or autonomous systems IP exist in any reviewed source; the classification as a robotics company is unsupported by evidence (Tracxn Company Profile, Feb 8, 2026).
— Contradictory funding status on Tracxn — listed as both 'funded' and 'unfunded' with no disclosed investors, round details, or amounts — erodes confidence in financial standing and data reliability (Tracxn Company Profile, Feb 8, 2026).
— No leadership team, founders, board members, or technical advisors are publicly disclosed, creating significant governance and execution risk (Tracxn Legal Entity Profile, Feb 3, 2026; Tracxn Company Profile, Feb 8, 2026).
— Zero verified hospital customers, deployments, pilots, or case studies; no press releases, product announcements, or partnership disclosures found in any source.
— Competitor set (Centivo, Access Healthcare, iMedX) aligns with healthcare benefits administration and RCM/BPO — not robotics — confirming a services/consulting positioning in a crowded, low-margin landscape (Tracxn Company Profile, Feb 8, 2026).
— No financial statements, revenue figures, headcount, or unit economics are publicly available, making any valuation or growth assessment impossible.
— Category misclassification risk: third-party databases may incorrectly tag the company as robotics/healthtech product company when it is a consulting micro-SME (Tracxn Company Profile, 2026).
— Data transparency risk: contradictory funding status and zero financial disclosures prevent any meaningful financial assessment.
— Execution risk: pivoting to hospital AMR integration or productization requires capital, talent, OEM partnerships, and safety expertise that are undemonstrated.
— Competitive risk: established AMR OEMs and global systems integrators are already active in Singapore's hospital automation market, creating high barriers to entry.
— Governance risk: absence of any named leadership or advisory team raises questions about operational continuity and accountability.
— Procurement cycle risk: hospital procurement is lengthy and requires robust internal champions and ROI evidence, neither of which the company has demonstrated.
— Public announcement of a hospital AMR partnership or pilot win in Singapore with a credible OEM partner.
— Disclosure of a named leadership team with relevant robotics, hospital operations, or safety credentials.
— Verified funding event with credible investors tied to a product or integration roadmap.
— Publication of hospital deployment outcomes with quantifiable ROI metrics (e.g., reduced portering time, improved logistics OTIF).
— Launch of a productized software offering (e.g., fleet orchestration, analytics dashboard) with named customers.